Health Related Quality of Life, Disability, and Pain in Alpha Mannosidosis: Long-Term Data of Enzyme Replacement Therapy With Velmanase Alfa (Human Recombinant Alpha Mannosidase). (3rd September 2018)

• Record Type: Journal Article
• Authors: Borgwardt, Line; Guffon, Nathalie; Amraoui, Yasmina; Jones, Simon A.; De Meirleir, Linda; Lund, Allan M.; Gil-Campos, Mercedes; Van den Hout, Johanna M. P.; Tylki-Szymanska, Anna; Geraci, Silvia; Ardigò, Diego; Cattaneo, Federica; Harmatz, Paul; Phillips, Dawn
• Is Part Of: Journal of inborn errors of metabolism and screening. Volume 6(2018)
• Publication Date: 2018-09-03
• Subjects: alpha-mannosidosis -- recombinant human alpha-mannosidase -- CHAQ -- EQ-5D-5L -- HRQoL -- disability; Metabolism, Inborn errors of -- Periodicals; Metabolism, Inborn errors of -- Diagnosis -- Periodicals; 616.3904205
• DOI: 10.1177/2326409818796854
• Languages: English
• ISSNs: 2326-4594

Abstract

Alpha-mannosidosis, a rare lysosomal storage disorder caused by deficiency of the lysosomal enzyme alpha-mannosidase, results in accumulation of mannose-rich glycoproteins in the tissues and sequelae leading to intellectual disability, ataxia, impaired hearing and speech, recurrent infections, skeletal abnormalities, muscular pain, and weakness. This study aimed to investigate disability, pain, and overall health using the Childhood Health Assessment Questionnaire (CHAQ) and the EuroQol 5 Dimension-5 Level Questionnaire (EQ-5D-5L) in patients with alpha-mannosidosis participating in rhLAMAN-10, a phase III open-label, clinical trial of velmanase alfa, a recombinant human lysosomal alpha-mannosidase. Long-term prognoses for most patients with untreated alpha-mannosidosis are poor due to progressive neuromuscular, skeletal, and intellectual deterioration, leading to increased dependence in mobility and activities of daily living and increased caregiver and health-care burden. Long-term CHAQ and EQ-5D-5L data highlight improvement trends in health-related quality of life and a reduction in disability and pain in patients receiving up to 48 months of velmanase alfa treatment.